Open AccessUtilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras
Author(s) -
Ali Raza Khaki,
Shasank Chennupati,
Catherine R. Fedorenko,
Li Li,
Qin Sun,
Petros Grivas,
Scott D. Ramsey,
Stephen M. Schwartz,
Veena Shankaran
Publication year - 2021
Publication title -
jco oncology practice
Language(s) - English
Resource type - Journals
eISSN - 2688-1535
pISSN - 2688-1527
DOI - 10.1200/op.20.01050
Subject(s) - medicine , systemic therapy , emergency department , cancer , emergency medicine , psychiatry , breast cancer
Systemic therapy use in the last 30 days of life (DOL) for patients with advanced cancer is a low-value medical practice. We hypothesized that systemic therapy use in the last 30 DOL increased after approval of antiprogrammed cell death protein 1 immune checkpoint inhibitors (ICIs) and has contributed to increased health care utilization and spending.